
Patent Law Weblog
recent posts
- Why the Alice Test is Stupid, Part IV: The Usefulness Paradox
- Teva Capitulates to Federal Trade Commission Coercion
- USPTO Issues Memoranda on Subject Matter Eligibility
- USPTO Revokes Guidance on AI-Assisted Inventorship, But Rules Remain Basically the Same
- Why the Alice Test is Stupid, Part III: Eligible Independent Claims Can Have Ineligible Dependent Claims
about
Category: Patent Profiles
-
By Kevin E. Noonan — Dennis Crouch, our colleague at Patently-O, tweeted last week that there have been 148 U.S. patents granted having disclosure related to (COVID-19 or SARS-CoV-2); see Search of U.S Patent and Trademark Office Patent Full-Text and Image Database and With regard to issues involving the proposed WTO IP waiver (see "If…
-
By Kevin E. Noonan — For several years, Sigma Aldrich has been prosecuting several applications (including USSNs 15/188,911; 15/188,924; and 15/456,204) claiming CRISPR technology that (it alleged) would be deserving of an interference with University of California's U.S. Application Nos. 15/9547,718 and 15/981,809, and reserving the right to supplement its request to include other patents…
-
By Kevin E. Noonan — On Tuesday, the U.S. Patent and Trademark Office granted U.S. Patent No. 10,385,360 to the University of California/Berkeley, directed to an aspect of its CRISPR technology (where CRISPR is an acronym for Clustered Regularly lnterspaced Short Palindromic Repeats). The independent claims of the '360 patent read as follows: 1. A…
-
By Kevin E. Noonan — Last Tuesday, the U.S. Patent and Trademark Office granted (at long last) to the University of California/Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier a patent corresponding to the application-in-interference with the Broad's patent estate, as U.S. Patent No. 10,266,850, to its CRISPR technology (where CRISPR is an acronym…
-
By Steve Kennedy* and Anthony D. Sabatelli** As reviewed previously, antibody-drug conjugates (ADCs) are a highly promising class of antitumor drugs that represent a growing proportion of cancer treatments in the development pipeline (see "Antibody Drug Conjugates: The Patent Landscape for a New Class of Cancer Treatment"). By combining the specificity of monoclonal antibodies targeted…
-
By Kevin E. Noonan — The U.S. Patent and Trademark Office today granted U.S. Patent 10,227,611 to Jennifer Doudna, Martin Jinek, Krzysztof Chylinski, and Emmanuelle Charpentier, the patent entitled "Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription" and assigned to the Regents of the University of California, the University…
-
By Brian Pattengale* and Anthony D. Sabatelli** — Lowering carbon dioxide (CO2) levels in our atmosphere is one of the most important challenges to be overcome in the next century. While fossil-fuel fired plants produce a visible smoke consisting almost entirely of water vapor, the invisible CO2 released along with it is the real concern. …
-
By Brian Pattengale* and Anthony D. Sabatelli** — Recent data from NOAA, the National Oceanic and Atmospheric Administration, indicates that current atmospheric carbon dioxide (CO2) levels are at 409 ppm as of October 2018. This is a 36% increase from the highest historical CO2 level,1 and is increasingly being attributed to human activity, namely fossil…
-
By Steve Kennedy* and Anthony D. Sabatelli** — As discussed in our previous article, antibody-drug conjugates (ADCs) have emerged as a highly promising class of anti-cancer drugs, and significant technical innovations are being made in all three components of the ADC, i.e., the antibody, the drug payload, and the linker joining them. The linker has…
-
By Kevin E. Noonan — The U.S. Patent and Trademark Office granted U.S. Patent No. 10,113,167 today to the University of California/Berkeley, directed to an aspect of its CRISPR technology (where CRISPR is an acronym for Clustered Regularly lnterspaced Short Palindromic Repeats). The interference between the Broad Institute and the University of California/Berkeley over patents…